[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386. [2] Ferlay J, Shin HR, Bray F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917. [3] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. [4] Shang GD, Dai JL, Wang YG.Construction and physiological studies on a stable bioengineered strain of Shengjimycin[J]. J Antibiot, 2001, 54(1): 66-73. [5] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. [6] Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma [J]. Int J Mol Sci, 2018, 19(8): piiE2413. [7] Pistritto G, Trisciuoglio D, Ceci C, et al.Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging, 2016, 8(4): 603-619. [8] Foster KG, Fingar DC.Mammalian target of Rapamycin (mTOR): conducting the cellular signaling symphony[J]. J Biol Chem, 2010, 285(19): 14071-14077. [9] Edelman MJ, Shvartsbeyn M.Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance[J]. Clin Lung Cancer, 2012, 13(3): 171-180. [10] Demain AL, Vaishnav P.Natural products for cancer chemotherapy[J]. Microb Biotechnol, 2011, 4(6): 687-699. [11] Eloy JO, Petrilli R, Chesca DL, et al.Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy[J]. Euro J Pharm Biopharm, 2017, 115: 159-167. [12] Chen J, Stubbe J.Bleomycins: towards better therapeutics[J]. Nat Rev Cancer, 2005, 5(2): 102-112. [13] Maximiliano C, Estefanía G, Ezequiel B, et al.Doxorubicin: nanotechnological overviews from bench to bedside[J]. Drug Discov Today, 2016, 22(2): 270-281. |